非氧化型甲状旁腺激素与慢性肾脏病心血管及肾脏结局的关联
在535例eGFR 89-15 ml/min/1.73 m²的CKD患者中,基线测量PTH和非氧化型PTH并随访5.1年。校正eGFR和尿白蛋白后,非氧化型PTH与任何临床结局均无关联,而PTH仍与急性心衰和全因死亡相关;进一步校正心血管和肾脏危险因素后,PTH仅与全因死亡相关。
要点
- 非氧化型PTH与CKD患者心血管事件、CKD进展及死亡均无独立关联。
- 校正eGFR和尿白蛋白后,PTH仍与急性心衰和全因死亡相关。
- 进一步校正危险因素后,PTH仅与全因死亡独立相关。
核心结论
- 在CKD患者中,PTH与全因死亡相关,而非氧化型PTH与所考察的任何临床结局均无关联。
研究设计与样本
- 前瞻性队列研究,纳入535例CKD患者,基线eGFR范围89-15 ml/min/1.73 m²,随访5.1年。
主要发现
- 随访期间发生动脉粥样硬化事件116例、急性心衰58例、CKD进展73例、全因死亡85例。
- 校正eGFR和尿白蛋白后,非氧化型PTH第三分位vs第一分位与动脉粥样硬化事件(HR 1.04,95%CI 0.62-1.75)、急性心衰(HR 1.24,95%CI 0.59-2.62)、CKD进展(HR 0.93,95%CI 0.46-1.90)及全因死亡(HR 1.23,95%CI 0.66-2.31)均无关联。
- 校正eGFR和尿白蛋白后,PTH第三分位vs第一分位与急性心衰(HR 2.76,95%CI 1.11-6.89)和全因死亡(HR 2.35,95%CI 1.13-4.89)相关,与动脉粥样硬化事件(HR 0.80,95%CI 0.46-1.38)和CKD进展(HR 0.99,95%CI 0.46-2.10)无关联。
- 进一步校正心血管和肾脏危险因素后,PTH第三分位vs第一分位仍与全因死亡相关(HR 2.79,95%CI 1.32-5.89),与其他终点无关联。
临床怎么用
- 在CKD患者中,传统PTH检测对全因死亡的预后价值可能优于非氧化型PTH检测。
- 非氧化型PTH目前不宜作为CKD患者心血管或肾脏结局的独立风险评估指标。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: In patients with CKD, elevated plasma parathyroid hormone (PTH) levels are associated with greater cardiovascular morbidity and mortality. However, the reference method for PTH measurement is disputed. It has been argued that measurement of nonoxidized PTH better reflects biologically active PTH than measurements with conventional assays. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: PTH and nonoxidized PTH levels were measured at study baseline in 535 patients with CKD with an eGFR range between 89 and 15 ml/min per 1.73 m2. Patients were followed over 5.1 years for the occurrence of acute heart failure, atherosclerotic events, CKD progression (doubling of serum creatinine or initiation of RRT), or all-cause death. RESULTS: Atherosclerotic events, acute heart failure, CKD progression, and deaths from any cause occurred in 116, 58, 73, and 85 patients, respectively. In Kaplan-Meier analyses, patients at the highest PTH and nonoxidized-PTH tertile (79-543 and 12-172 pg/ml, respectively) showed a higher rate of atherosclerotic events, acute heart failure, CKD progression, and death from any cause. After adjustment for eGFR and albuminuria, nonoxidized PTH was no longer associated with atherosclerotic events (hazard ratio third versus first tertile, 1.04 [95% confidence intervals, 0.62-1.75]), acute heart failure (hazard ratio third versus first tertile, 1.24 [95% confidence intervals, 0.59-2.62]), CKD progression (hazard ratio third versus first tertile, 0.93 [95% confidence intervals, 0.46-1.90]), and death from any cause (hazard ratio third versus first tertile, 1.23 [95% confidence intervals, 0.66-2.31]), and PTH lost its association with atherosclerotic events (hazard ratio third versus first tertile, 0.80 [95% confidence intervals, 0.46-1.38]) and CKD progression (hazard ratio third versus first tertile, 0.99 [95% confidence intervals, 0.46-2.10]), although it remained associated with acute heart failure (hazard ratio third versus first tertile, 2.76 [95% confidence intervals, 1.11-6.89]) and all-cause death (hazard ratio third versus first tertile, 2.35 [95% confidence intervals, 1.13-4.89]). After further adjustment for cardiovascular and kidney risk factors, PTH remained associated with all-cause death (hazard ratio third versus first tertile, 2.79 [95% confidence intervals, 1.32-5.89]), but with no other end point. CONCLUSIONS: In a cohort of patients with CKD, PTH was associated with all-cause mortality; there was no association of nonoxidized PTH with any of the clinical outcomes examined.
引用
- Seiler-Mussler S, Limbach AS, Emrich IE, et al. Association of Nonoxidized Parathyroid Hormone with Cardiovascular and Kidney Disease Outcomes in Chronic Kidney Disease. Clin J Am Soc Nephrol. 2018. PMID: 29507005. doi:10.2215/CJN.06620617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。